January 04, 2021
REDWOOD CITY, Calif. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...
Read MoreDecember 11, 2020
Soleno intends to submit plans to FDA to conduct further analyses of clinical data from ...
Read MoreNovember 10, 2020
REDWOOD CITY, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...
Read More
Developing novel therapeutics for the treatment of rare diseases.
Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome